Post Op Positive Apex Margins Case 3: Prostate_3

Slides:



Advertisements
Similar presentations
Advanced Stage Prostate Cancer Management Michael E. Karellas Assistant Professor of Urologic Oncology May 15, 2010.
Advertisements

THE CLINICO-PATHOLOGIC PATTERNS OF PROSTATIC DISEASES AND PROSTATE CANCER IN SAUDI PATIENTS Hisham A. M. Mosli, FRCSC, FACS Taha A. Abdel-Meguid, MD Jaudah.
The PRIAS Study In Australia One Institution’s Experience Introduction PRIAS (Prostate cancer Research International: Active Surveillance – NTR1718) is.
Stephen Ko, M.D. Mayo Clinic Jacksonville
In biochemical recurrence after curative treatment of prostate cancer, Choline PET/CT 1- has a detection rate of 10-20% when PSA: 1-2 ng/ml 2- has a detection.
Radiotherapy in prostate cancer Dr.Mina Tajvidi Radiation oncologist.
Role of MRI and MRSI in The Management of Prostate Cancer Karim Touijer, MD.
Radical Prostatectomy Sept 2009 till Aug 2010 South Mersey Cancer Network Manal Kumar Consultant Urologist.
PROSTATE CANCER EXPECTED MANAGEMENT & CURATIVE TREATMENT Dr. Abdullah A. Ghazi (R5) KSMC.
Expectant Management of Prostate Cancer James A. Eastham, MD and Peter T. Scardino, MD June 23, 2010 Presented by: K. Witzke, DO.
Prostate Radiotherapy A-Z
PROSTATE CANCER LETS DEBATE !!!! Dr Fred C Tyler MBChB FRCS FCS UROL.
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
Prostate cancer: To screen or not to screen – To treat or not to treat Dr Oliver Klein – Medical Oncologist.
Howard M. Sandler, MD University of Michigan Medical School
RISK OF NON SIGNIFICANT PROSTATE CANCER IN PROSTATE CANCER PATIENTS DIAGNOSED BY AN EXTENDED PROSTATE NEEDLE BIOPSY PROCEDURE AND TREATED BY RADICAL PROSTATECTOMY.
Prostate Cancer Case Presentation Shireen Siddiqui.
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
Prostate Cancer Prostate cancer is the most common cancer detected in American men. The lifetime risk of a 50-year-old man for latent CaP is 40%; for.
Dan Spratt, MD Department of Radiation Oncology Neuroendocrine Prostate Cancer: FDG-PET and Targeted Molecular Imaging.
A 74 year old man underwent open prostatectomy due to moderate to severe urinary symptoms unresponsive to medical therapy. Preoperative PSA was 4.1 Postoperatively.
Prostate Cancer: A Case for Active Surveillance Philip Kantoff MD Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School.
NYU Medical Grand Rounds Clinical Vignette Josie Ni, PGY-3 9/13/11 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
Laparoscopic Radical Prostatectomy: Oncological and Functional Outcomes Following Fellowship Training. Introduction Radical Prostatectomy (RP) is a technically.
CASE 1 65-year-old man No other diseases or previous surgeries July 2005: PSA 11.5 ng/ml; F/T: 9% After prostate biopsy revealing adenocarcinoma: RETROPUBIC.
Prostate Cancer: Treatment choices Prostate Cancer: Treatment choices Winston W Tan MD FACP Winston W Tan MD FACP Senior Consultant Senior Consultant Genitourinary.
TNM Staging: Prostate TONYA BRANDENBURG, MHA, CTR KENTUCKY CANCER REGISTRY.
Postsurgical Risk Factors for Prostate Cancer Mortality Slideset on: Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer–specific mortality.
Carcinoma of the prostate. INTRODUCTION Prostate cancer is the most common cancer diagnosed and is the second leading cause of cancer death in men in.
IMPACT OF STAGE MIGRATION ON NODE POSITIVE PROSTATE CANCER RATE AND FEATURES: A 20-YEAR, SINGLE INSTITUTION ANALYSIS IN MEN TREATED WITH EXTENDED PELVIC.
Professor Guram Karazanashvili MD, KMSc, DMSc MMT Hospital.
International Neurourology Journal 2015;19:
Volume 155, Issue 3, Pages (March 1996)
Philipp Dahm, Ari D. Silverstein, Alon Z
Surgical Treatment in Locally Advanced Prostate Cancer
Professor Guram Karazanashvili MD, KMSc, DMSc MMT Hospital
Bladder Cancer and Prostatic Cancer
J. Edson PontesM.D. Professor Urologic Oncology WSU/KCI
The PSA Era is not Over for Prostate Cancer
Department of Radiation Oncology, Shuang Ho Hospital Yu Jen Wang MD
Nat. Rev. Urol. doi: /nrurol
New Tracers for Prostate Cancer Imaging
New perioperative risk factors for biochemical recurrence after robotic assisted radical prostatectomy: A single surgeon experience in high volume Canadian.
2327 PROSTATE CANCER STAGE, GRADE AND POSITIVE MARGIN RATE IN MEN WITH PSA ≥ 1 ng/ml UNDERGOING RADICAL PROSTATECTOMY: POPULATION DATA ANALYSIS  Sergey.
RELAZIONE TRA “STAGE MIGRATION” E
RTOG 0126 A Phase III Randomized Study of High Dose 3D-CRT/IMRT versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer Bijoy.
Post Op Positive Seminal Vesicle Case 4: Prostate_4
Prostate Cancer: Highlights from 2006
Jaden D. Evans, MD, Krishan R
ROBOTIC ASSISSTED RADICAL PROSTATECTOMY OUR INITIAL EXPERIENCE
Apollo Gleneagles Hospitals,
Volume 67, Issue 3, Pages (March 2015)
Volume 62, Issue 2, Pages (August 2012)
Advances in the Treatment of Metastatic Prostate Cancer
Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance  Adam B. Weiner, Ruth Etzioni, Scott E. Eggener 
Volume 62, Issue 1, Pages (July 2012)
Retrograde Nerve-Sparing (NS) Laparoscopic Radical Prostatectomy (LRP): Technical Aspects and Early Results  Jens J. Rassweiler, Marto Sugiono, Marcel.
The PSA Era is not Over for Prostate Cancer
Nat. Rev. Urol. doi: /nrurol
EARLY AND LATE COMPLICATIONS OF PROSTATE LOW DOSE BRACHYTHERAPY
External Beam Radiotherapy as Curative Treatment of Prostate Cancer
Volume 58, Issue 1, Pages 1-7 (July 2010)
Figure 1. Non-biochemical recurrence rate for the entire population (n = 122). From: Salvage radiation therapy for prostate cancer patients after prostatectomy.
Antonio Alcaraz, Pierre Teillac  European Urology Supplements 
What's New in Prostate Cancer: Highlights from Urologic and Oncologic Congresses in 2006  Michel Soulié, Nicolas Mottet, Laurent Salomon, Jacques Irani,
Disease-specific survival
Prostate Cancer Update
Fernando P. Secin, Fernando J. Bianco, Nicholas T
History: 71 yo male post radical prostatectomy 4 years ago for Gleason 4+5 prostate cancer Pre-op staging CT and MDP bone scan were negative for metastatic.
Surgery for high-risk prostate cancer: The results of first 80 cases
Presentation transcript:

Post Op Positive Apex Margins Case 3: Prostate_3 A 59-year-old gentleman with a preop clinical T1c, Gleason 7 (3+4) PSA 12 adenocarcinoma of the prostate. He is status post radical retro pubic prostatectomy and found to have pathologic T2c, Gleason Score 7 (3+4) disease. Pathology reveals margins positive bilaterally at the apex. His PSA went to undetectable for 2 years then rose to 0.2 and 6 months later was 0.3 ng/ml. Please draw the CTV-TB (CTV for the tumor bed/prostate bed for this case). www.rtog.org www.rtog.org

end